Anti-retrovirals Flashcards
In the treatment of HIV
a. indinavir prevents the synthesis of HIV DNA
A. False. Indinavir is a protease inhibitor
In the treatment of HIV
b. zidovudine is a protease inhibitor
B. False, zidovudine is nucleoside reverse transcriptase inhibitor
In the treatment of HIV
c. lopinavir causes hyperlipidaemia as an adverse effect
C. True, PI cause insulin resistance, hyperglycaemia, diarrhea, dyslipidemia, lipodystrophy, atherosclerosis, hepatitis, osteoporosis, osteonecrosis as AEs
In the treatment of HIV
d. zidovudine is more likely to cause anaemia than lamivudine
D. True. Zidovudine is the big one.
In the treatment of HIV
e. didanosine is used to treat stavudine-induced lactic acidosis
E. False, didanosine and stavudine greatly increase the risk of lactic acidosis
In the management of HIV
a. tenofovir is a HIV nucleotide reverse transcriptase enzyme inhibitor (NRTI)
A. True
In the management of HIV
b. ritonavir causes inhibition of CYP3A4
B. True. Ritonavir is a potent inhibitor of CYP3A4
In the management of HIV
c. lopinavir inhibits the action of HIV protease
C. True
In the management of HIV
d. nevirapine inhibits DNA gyrase
D. False, nevirapine is a NNRTI and inhibits reverse transcriptase. Fluoroquinolones inhibit DNA gyrase
In the management of HIV
e. rifampicin increases the plasma levels of lopinavir
E. False, lopinavir is metabolised by CYP3A4 enzymes, which are induced by rifampicin
Lopinavir + ritonavir combination
a. inhibits HIV reverse transcriptase
A. False, PI inhibit HIV protease
Lopinavir + ritonavir combination
b. induces cytochrome P450 enzymes
B. False. The role of ritonavir in this combination is to act as a pharmacokinetic, enhancer, inhibiting CYP3A4 hence inhibit the metabolism of lopinavir
Lopinavir + ritonavir combination
c. causes insulin resistance as an adverse effect
C. True, PIs cause insulin resistance
Lopinavir + ritonavir combination
d. is a protease inhibitor
D. True
Lopinavir + ritonavir combination
e. causes lipodystrophy
E. True, Pis cause lipodystrophy
In the treatment of HIV
a. nevirapine is a direct inhibitor of reverse transcriptase
A. False, NNRTIs are indirect inhibitors of reverse transcriptase (allosteric inhibition)
In the treatment of HIV
b. lamivudine causes peripheral neuropathy as an adverse effect
B. True, NRTIs cause peripheral neuropathy as an adverse effect
In the treatment of HIV
c. efavirenz requires phosphorylation to its active form
C. False, NNRTIs don’t require phosphorylation
In the treatment of HIV
d. tenofivir is contraindicated in severe renal failure
D. True, tenofovir (TDF) causes nephrotoxicity
In the treatment of HIV
e. zidovudine is a cytosine analogue
E. False, thymidine analogue
In the treatment of HIV:
a. nevirapine is hepatotoxic
a. True. NNRTIs are hepatoxic
In the treatment of HIV:
b. efavirenz causes sleep disturbances
b. True
In the treatment of HIV:
c. nevirapine increases the risk of Stevens Johnson syndrome
c. True
In the treatment of HIV:
d. efavirenz is a nucleoside reverse transcriptase inhibitor
d. False, NNRTI
In the treatment of HIV:
e. nevirapine is used in combination with lamivudine as part of triple therapy
e. True, in neonates give Zidovudine (AZT) + Lamivudine (3TC) + Nevirapine (NVP)
Lamivudine
a. is a non-nucleoside reverse transcriptase inhibitor
a. False. NRTI
Lamivudine
b. causes peripheral neuropathy as an adverse effect
b. True, NRTIs causes peripheral neuropathy
Lamivudine
c. is more toxic to the mitochondrion than zidovudine
c. False, zidovudine, didansoine and stavudine are the most toxic towards mitochondria. Mitochondrial toxicity is characterised by: peripheral neuropathy, pancreatitis, lipodystrophy syndrome, hepatic steatosis and myopathy
Lamivudine
d. is used in combination with emtricitabine
d. False, either Emtricitabine (FTC) or Lamivudine (3TC)
Lamivudine
e. has activity against Hepatitis B
e. True
Non-nucleoside reverse transcriptase inhibitors (NNRTI)
a. efivarenz is hepatotoxic
a. True
Non-nucleoside reverse transcriptase inhibitors (NNRTI)
b. efivarenz is safe to use in patients with schizophrenia
b. False, cause neurocognitive impairment
Non-nucleoside reverse transcriptase inhibitors (NNRTI)
c. nevirapine causes Stevens Johnson syndrome
c. True
Non-nucleoside reverse transcriptase inhibitors (NNRTI)
d. efivarenz induces cytochrome P450 enzymes
d. False, metabolised by CYP450 enzymes.
Non-nucleoside reverse transcriptase inhibitors (NNRTI)
e. efivarenz and nevirapine are combined as part of triple therapy in HIV
e. False, triple therapy includes 2 NRTIs + NNRTI/ Integrase inhibitor.
Tenofovir
a. is contraindicated in patients with advance kidney disease
a. True, nephrotoxic
Tenofovir
b. is used in combination with lamivudine as part of triple therapy in HIV
b. True
Tenofovir
c. compared to zidovudine, has a higher risk for causing lactic acidosis
c. False, both cause
Tenofovir
d. is a protease reverse transcriptase inhibitor
d. False, NRTI
Tenofovir
e. is a nucleotide anologue of adenosine
e. True
tenofovir is an HIV protease inhibitor
False, NRTI
lamivudine causes peripheral neuropathy as an adverse effect
True
zidovudine inhibits reverse transcriptase
True
nevirapine causes hepatotoxicity as an adverse effect
True
lopinavir decreases blood glucose levels
False
Increases
Antiretroviral agents
a. zidovudine inhibits reverse transcriptase
a. true, NRTI
Antiretroviral agents
b. nevirapine prevents the synthesis of viral DNA
b. true, NNRTI
Antiretroviral agents
c. efavirenz is contraindicated during pregnancy
c. False, indicated, dolutegravir is risky
- In the management of HIV
a. tenofovir is a HIV nucleotide reverse transcriptase enzyme inhibitor (NRTI)
a. True
In the management of HIV
b. ritonavir causes inhibition of CYP3A4
b. True
In the management of HIV
c. lopinavir inhibits the action of HIV protease
c. True
In the management of HIV
d. nevirapine inhibits DNA gyrase
d. False, NNRTI
In the management of HIV
e rifampicin increases the plasma levels of lopinavir
e. False, induces p450 enzymes